Overall, while xentuzumab could be safely combined with everolimus and exemestane, the addition of xentuzumab did not improve PFS in patients with HR-positive, HER2-negative advanced breast cancer with non-visceral disease. Here, ERBB2 is linked to breast carcinoma.